Loading
Life sciences · Journal article
ESMO Real World Data and Digital Oncology · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Early treatment discontinuation (ETD) is common in cancer treatment but understudied. We sought to identify clinical and treatment-related factors associated with ETD in a real-world cohort of patients with non-small-cell lung cancer (NSCLC). Patients and methods We analyzed lines of therapy (LoTs) including drugs intended for an indefinite treatment sourced from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative NSCLC cohort. Associations between treatment exposure and ETD were evaluated using multivariable logistic regression adjusting for age at LoT initiation, sex, stage, and context (first-line, second-line, third-line, or later). Sensitivity analyses examined mutation-specific targeted therapy exposures and ETD within 14 days of death. Results ETD occurred in 883 of 2098 eligible LoTs (42%). Programmed cell death protein 1/programmed death-ligand 1 inhibitor exposure was associated with higher odds of ETD [odds ratio (OR) = 2.07, 95% confidence interval (CI) 1.27-3.38], whereas small-molecule inhibitor exposure was associated with lower odds (OR = 0.43, 95% CI 0.26-0.70). Context showed a graded increase in ETD risk: second-line versus first-line (OR = 1.46, 95% CI 1.14-1.87) and third-line or later versus first-line (OR = 2.63, 95% CI 2.09-3.32). In 302 LoTs with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in patients with EGFR -activating mutations, EGFR TKI naivety was associated with lower odds of ETD (OR = 0.34, 95% CI 0.19-0.59). Eighty LoTs ended within 14 days of death, of which 54 (68%) were ETDs. Conclusions ETD in NSCLC is associated with treatment modality, timing, and biology. The drivers of ETD are complex and span medical, social, and psychological domains. This study highlights ETD as a measurable quantity and provides a framework for future studies.